BioPharmSignal logoBioPharmSignal

Biotech News

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Emergent BioSolutions (EBS)Emergent BioSolutionsEarnings

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026. Participants can access the conference call live via

Related news

EBSEmergent BioSolutions2026-04-30 20:30 EST

Emergent BioSolutions Reports First Quarter 2026 Financial Results

EBSEmergent BioSolutions2026-04-16 20:05 EST

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

View all latest news

Emergent BioSolutions

Emergent BioSolutions is a biodefense and specialty products company focused on public-health preparedness, vaccines, and medical countermeasures. Its business is centered on government and specialty healthcare contracts.

Recent company news

EBSEmergent BioSolutions2026-05-28 20:01 EST

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

EBSEmergent BioSolutions2026-05-20 11:30 EST

Emergent BioSolutions to Participate in Upcoming Investor Conferences

EBSEmergent BioSolutions2026-05-18 12:59 EST

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

EBSEmergent BioSolutions2026-04-30 20:30 EST

Emergent BioSolutions Reports First Quarter 2026 Financial Results

EBSEmergent BioSolutions2026-04-30 11:55 EST

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Stock data

Close
4.82 USD
Market cap
423.61M USD
Exchange
NYSE
Sector
Biopharma
Location
United States